CA2559662A1 - Nouvelles alternatives aux antibiotiques - Google Patents

Nouvelles alternatives aux antibiotiques Download PDF

Info

Publication number
CA2559662A1
CA2559662A1 CA002559662A CA2559662A CA2559662A1 CA 2559662 A1 CA2559662 A1 CA 2559662A1 CA 002559662 A CA002559662 A CA 002559662A CA 2559662 A CA2559662 A CA 2559662A CA 2559662 A1 CA2559662 A1 CA 2559662A1
Authority
CA
Canada
Prior art keywords
colicin
coli
recombinant
vector construct
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002559662A
Other languages
English (en)
Inventor
Chad H. Stahl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iowa State University Research Foundation ISURF
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2559662A1 publication Critical patent/CA2559662A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002559662A 2004-03-15 2005-03-15 Nouvelles alternatives aux antibiotiques Abandoned CA2559662A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55320904P 2004-03-15 2004-03-15
US60/553,209 2004-03-15
PCT/US2005/008512 WO2005089812A2 (fr) 2004-03-15 2005-03-15 Nouvelles alternatives aux antibiotiques

Publications (1)

Publication Number Publication Date
CA2559662A1 true CA2559662A1 (fr) 2005-09-29

Family

ID=34962848

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002559662A Abandoned CA2559662A1 (fr) 2004-03-15 2005-03-15 Nouvelles alternatives aux antibiotiques

Country Status (5)

Country Link
EP (1) EP1730178A2 (fr)
AU (2) AU2005222636B2 (fr)
CA (1) CA2559662A1 (fr)
MX (1) MXPA06010457A (fr)
WO (1) WO2005089812A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592159B2 (en) 2004-03-15 2009-09-22 Iowa State University Research Foundation, Inc. Antibiotic alternatives
US20060270040A1 (en) * 2005-05-26 2006-11-30 Conjugon, Inc. Compositions and methods for treating tissue
MX2009011385A (es) * 2007-05-08 2010-02-18 Biotechnology Res & Dev Optimizacion de produccion de colicina.
CN101643501B (zh) * 2008-11-07 2012-06-20 畿晋庆三联(北京)生物技术有限公司 一种新型抗生素及其核苷酸序列、制备方法与应用
EP3097783B1 (fr) * 2015-05-26 2019-11-13 Nomad Bioscience GmbH Colicine m pour le contrôle de ehec

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965128A (en) * 1997-08-13 1999-10-12 University Of Georgia Research Foundation Inc. Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli

Also Published As

Publication number Publication date
MXPA06010457A (es) 2006-12-14
EP1730178A2 (fr) 2006-12-13
AU2005222636A1 (en) 2005-09-29
WO2005089812A2 (fr) 2005-09-29
AU2009243505A1 (en) 2009-12-24
AU2005222636B2 (en) 2009-09-03
WO2005089812A3 (fr) 2006-05-26

Similar Documents

Publication Publication Date Title
Ullah et al. Purification and primary characterization of a novel bacteriocin, LiN333, from Lactobacillus casei, an isolate from a Chinese fermented food
Peng et al. A broad-spectrum novel bacteriocin produced by Lactobacillus plantarum SHY 21–2 from yak yogurt: Purification, antimicrobial characteristics and antibacterial mechanism
US7592159B2 (en) Antibiotic alternatives
KR101793498B1 (ko) 유산균 균주, 바실러스 속 균주 및 효모 균주를 이용한 고상발효에 의한 항균활성 및 효소활성을 가지는 사료 첨가용 다기능 생균제의 제조방법 및 그에 따른 사료 첨가용 다기능 생균제
Valledor et al. Characterization and safety evaluation of two beneficial, enterocin-producing Enterococcus faecium strains isolated from kimchi, a Korean fermented cabbage
US20220088094A1 (en) Probiotic compositions comprising lactobacillus reuteri strains and methods of use
EP2771476B1 (fr) Streptococcus dysgalactiae id9103 et procédé de production d'acide hyaluronique l'utilisant
Izquierdo et al. Enterocin 96, a novel class II bacteriocin produced by Enterococcus faecalis WHE 96, isolated from Munster cheese
CA2711425A1 (fr) Activite antimicrobienne de bacteries a acide lactique productrices de bacteriocines
AU2005222636B2 (en) Novel antibiotic alternatives
US20140148379A1 (en) Control of Unwanted Bacteria in Fermentation Systems with Bacteriocin
TWI609081B (zh) 內酯酶的用途及利用內酯酶降解 α-玉米赤黴烯醇的方法
Kim et al. Identification and characterization of a bacteriocin produced by an isolated Bacillus sp. SW1-1 that exhibits antibacterial activity against fish pathogens
CN113557027A (zh) 用于治疗胃肠道病原体的工程抗微生物益生菌的联合
Naimi et al. Impact of microcin J25 on the porcine microbiome in a continuous culture model
KR20130068839A (ko) 티라민과 히스타민 분해능을 갖는 바실러스 리케니포미스 균주 및 이의 용도
KR101494230B1 (ko) 바실러스 아밀로리쿼파시엔스의 신규 변이주 및 이를 포함하는 동물사료 첨가제
KR20090088630A (ko) 프로테우스 미라빌리스 유래 아미노산 탈아미노화 효소유전자, 단백질, 재조합 벡터 및 형질전환체, 및 이를사용하여 기능성 유기산을 제조하는 방법
KR101177358B1 (ko) 펩티다아제 활성이 있는 엔돌라이신 LysB4, 이를 포함하는 식품 및 사료 조성물
Shamsudin et al. Probiotic properties of Lactobacillus isolates from chicken intestines
Abdelbasset et al. Purification and characterization of a novel bacteriocin produced by Lactobacillus curvatus LB65, isolated from Algerian traditional fresh cheese (Jben)
Al-Jumaily et al. Optimal conditions for acidocin production from Lactobacillus acidophilus isolate
Elegado et al. Antagonism against Listeria spp. and Staphyloccocus aureus by bacteriocin-producing lactic acid bacteria screened from the intestine of Philippine carabao, using polymerase chain reaction
CN1284560A (zh) 代谢产物的发酵制备方法及编码sod基因的核苷酸序列
Dwivedi et al. Increasing The Yield of Bacteriocin Produced by Lactobacillus Planta-rum Using Suspension Culture, J of Vacci Medicine & Health Care 1 (1), 01-04

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead